科研細(xì)胞
診斷試劑
技術(shù)服務(wù)
關(guān)于我們
聯(lián)系我們
藥靶模型
Drug Target Model
CBP75066
I. Background | |
FGFR2 gene at human chromosome 10q26 encodes FGFR2b and FGFR2c isoforms functioning as FGF receptors with distinct expression domain and ligand specificity. FGFR2 plays oncogenic and anti-oncogenic roles in a context-dependent manner. Single nucleotide polymorphisms (SNPs) within intron 2 of FGFR2 gene are associated with breast cancer through allelic FGFR2 upregulation. Missense mutations or copy number gains of FGFR2 gene occur in breast cancer and gastric cancer to activate FGFR2 signaling. Aberrant FGFR2 signaling activation induces proliferation and survival of tumor cells. The class switch from FGFR2b to FGFR2c occurs during progression of prostate cancer and bladder cancer because of spliceosome dysregulation. | |
II. Introduction | |
Host Cell: | HEK293 |
Expressed gene: | FGFR2C |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | DMEM+10%FBS+100ug/ml hygromyin |
Storage: | Liquid nitrogen |
III. Description of Host Cell Line | |
Organism: | Homo sapiens, human |
Tissue: | Embryonic kidney |
Disease: | Normal |
Morphology: | Epithelial |
Growth Properties: | Adherent |
IV. Representative Data | |